Marshall Wace’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-162,908
| Closed | -$3.28M | – | 3452 |
|
|
2026
Q1 | $3.28M | Buy |
+162,908
| New | +$2.63M | ﹤0.01% | 1525 |
|
|
2025
Q4 | – | Sell |
-370,773
| Closed | -$4.52M | – | 3209 |
|
|
2025
Q3 | $4.52M | Buy |
370,773
+251,151
| +210% | +$3.47M | ﹤0.01% | 1222 |
|
|
2025
Q2 | $1.35M | Buy |
119,622
+38,657
| +48% | +$473K | ﹤0.01% | 1728 |
|
|
2025
Q1 | $934K | Sell |
80,965
-37,013
| -31% | -$378K | ﹤0.01% | 1813 |
|
|
2024
Q4 | $999K | Buy |
117,978
+103,072
| +691% | +$1.07M | ﹤0.01% | 1739 |
|
|
2024
Q3 | $173K | Sell |
14,906
-34,005
| -70% | -$428K | ﹤0.01% | 2312 |
|
|
2024
Q2 | $576K | Sell |
48,911
-579,976
| -92% | -$6.77M | ﹤0.01% | 1910 |
|
|
2024
Q1 | $7.46M | Buy |
+628,887
| New | +$8.38M | 0.01% | 851 |
|
|
2023
Q4 | – | Sell |
-51,524
| Closed | -$496K | – | 2400 |
|
|
2023
Q3 | $496K | Buy |
+51,524
| New | +$526K | ﹤0.01% | 1733 |
|
|
2023
Q1 | – | Sell |
-18,396
| Closed | -$124K | – | 2889 |
|
|
2022
Q4 | $124K | Buy |
+18,396
| New | +$98.5K | ﹤0.01% | 2769 |
|
|
2022
Q3 | – | Sell |
-133,687
| Closed | -$1.32M | – | 3569 |
|
|
2022
Q2 | $1.32M | Buy |
133,687
+97,328
| +268% | +$1.07M | ﹤0.01% | 2276 |
|
|
2022
Q1 | $536K | Buy |
+36,359
| New | +$522K | ﹤0.01% | 2746 |
|
|
2021
Q3 | – | Sell |
-16,996
| Closed | -$407K | – | 3234 |
|
|
2021
Q2 | $407K | Sell |
16,996
-20,447
| -55% | -$535K | ﹤0.01% | 2224 |
|
|
2021
Q1 | $962K | Buy |
+37,443
| New | +$984K | ﹤0.01% | 1689 |
|
|
2020
Q2 | – | Sell |
-18,454
| Closed | -$141K | – | 1767 |
|
|
2020
Q1 | $141K | Buy |
+18,454
| New | +$249K | ﹤0.01% | 1260 |
|
|
2019
Q2 | – | Sell |
-29,452
| Closed | -$843K | – | 1597 |
|
|
2019
Q1 | $843K | Buy |
+29,452
| New | +$638K | 0.01% | 990 |
|
Other funds holding KALV
Marshall Wace's KALV Position: Q2 2026 in Review
Marshall Wace sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 162,908 shares — an estimated $3.28M sold.
Marshall Wace first reported a position in KALV in Q1 2019 and held it in 16 quarters. The position peaked at $7.46M in Q1 2024. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Marshall Wace reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Marshall Wace sold 162,908 KalVista Pharmaceuticals shares in Q2 2026, an estimated $3.28M.
- Marshall Wace first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 16 quarters.
- Marshall Wace's KalVista Pharmaceuticals position peaked at $7.46M in Q1 2024.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.